MDS Sciex

Applied Biosystems Group

March 01, 2005 07:00 ET

Applied Biosystems/MDS SCIEX and Phenomenome Discoveries Announce Metabolomics Agreement






MARCH 1, 2005 - 07:00 ET

Applied Biosystems/MDS SCIEX and Phenomenome
Discoveries Announce Metabolomics Agreement

FOSTER CITY, CALIFORNIA--(CCNMatthews - March 1, 2005) -

Software Compatibility for Applied Biosystems/MDS SCIEX Mass

Applied Biosystems (NYSE:ABI), an Applera Corporation, together with its
partner MDS Sciex, a division of MDS Inc. (TSX:MDS)(NYSE:MDZ), and
Phenomenome Discoveries, Inc.(PDI), a leading provider in comprehensive,
non-targeted metabolomics analysis, today announced a collaboration to
develop software for metabolomics analysis for certain Applied
Biosystems/MDS SCIEX mass spectrometers.

Under the agreement, PDI will customize its proprietary non-targeted
metabolomics analysis software for use on Applied Biosystems/MDS SCIEX
4000 Q TRAP® and QSTAR® XL LC/MS/MS Systems, and will ensure
compatibility with Analyst® Software, the data acquisition and
analysis software for the Applied Biosystems/MDS SCIEX instruments. PDI
will use the systems for sample analysis for both internal research
projects and external contract work in conjunction with its analysis
software, and provide performance input regarding current Applied
Biosystems/MDS SCIEX mass spectrometry software and hardware platforms.

"We believe that together, the QSTAR® XL and 4000 Q TRAP® LC/MS/MS
Systems form the most powerful LC-based metabolomics platform available
in the marketplace. This collaboration should address the growing needs
of metabolomics investigators by establishing analytical methods,
bioinformatics solutions, and workflows that suit their applications,"
said John Hyshka, COO and co-founder of Phenomenome Discoveries. "By
partnering with Applied Biosystems/MDS SCIEX, the leading provider of MS
systems, our mutual customers in industry, pharma, and academia will be
much better equipped to carry out their research."

"We are pleased to be entering into this agreement with Phenomenome
Discoveries, a market leader in the metabolomics arena. This
collaboration supports Applied Biosystems' overall metabolomics strategy
of providing complete solutions to our customers through external
collaboration or internal development projects," said Laura Lauman,
Division President, Proteomics and Small Molecule, for Applied

"The result of this collaboration should be a more integrated solution
for data generation and analysis for our customers," said Dr. Andy
Boorn, President of MDS Sciex.

About Applera Corporation and Applied Biosystems

Applera Corporation consists of two operating groups. The Applied
Biosystems Group serves the life science industry and research community
by developing and marketing instrument-based systems, consumables,
software, and services. Customers use these tools to analyze nucleic
acids (DNA and RNA), small molecules, and proteins to make scientific
discoveries, develop new pharmaceuticals, and conduct standardized
testing. Applied Biosystems is headquartered in Foster City, CA, and
reported sales of $1.7 billion during fiscal 2004. The Celera Genomics
Group (NYSE:CRA) is engaged principally in the discovery and development
of targeted therapeutics for cancer, autoimmune and inflammatory
diseases. Celera Genomics is leveraging its proteomic, bioinformatic,
and genomic capabilities to identify and validate drug targets, and to
discover and develop small molecule therapeutics. It is also seeking to
advance therapeutic antibody and selected small molecule drug programs
in collaboration with global technology and market leaders. Celera
Diagnostics, a 50/50 joint venture between Applied Biosystems and Celera
Genomics, is focused on discovery, development, and commercialization of
diagnostic products. Information about Applera Corporation, including
reports and other information filed by the company with the Securities
and Exchange Commission, is available at, or by
telephoning 800.762.6923. Information about Applied Biosystems is
available at

About MDS Sciex and MDS Inc.

MDS Sciex is the analytical instrumentation and technology solutions
division of MDS Inc. At MDS Inc., our 9,000 highly skilled people
provide services and products, which enable health sciences
organizations to enhance the well being of people around the world. We
focus on helping discover and test new drugs, assisting doctors to
diagnose and treat patients and preventing the spread of disease. Find
out more about MDS Inc. (TSX: MDS; NYSE: MDZ), at or by
calling 1-888-MDS-7222, 24 hours a day.

About Phenomenome Discoveries

Phenomenome Discoveries Inc. is a privately owned company located in
Saskatoon, Canada. Processing samples since December 2000, Phenomenome
is the first company in the world to make non-targeted metabolomic
investigation of complex biological samples commercially available using
its proprietary DISCOVAmetrics™ metabolite analysis and informatics
platform. Phenomenome Informatics, a division of Phenomenome Discoveries
Inc, in November 2004 launched Phenomenome Profiler™, the first
instrument-independent informatics platform designed for the
visualization and interpretation of mass spectrometry small molecule
data. Phenomenome has in-house and collaborative research programs in
human health, pharmacometabolomics, and agriculture.

Applied Biosystems Forward Looking Statements

Certain statements in this press release are forward-looking. These may
be identified by the use of forward-looking words or phrases such as
"believe," "anticipate," and "planned," among others. These
forward-looking statements are based on Applera Corporation's current
expectations. The Private Securities Litigation Reform Act of 1995
provides a "safe harbor" for such forward-looking statements. In order
to comply with the terms of the safe harbor, Applera Corporation notes
that a variety of factors could cause actual results and experience to
differ materially from the anticipated results or other expectations
expressed in such forward-looking statements. The risks and
uncertainties that may affect the operations, performance, development,
and results of Applied Biosystems include but are not limited to: (1)
rapidly changing technology could adversely affect demand for Applied
Biosystems' products, and its business is dependent on development of
new products; (2)Applied Biosystems' sales are dependent on customers'
capital spending policies and government-sponsored research; and (3)
other factors that might be described from time to time in Applera
Corporation's filings with the Securities and Exchange Commission. All
information in this press release is as of the date of the release, and
Applera does not undertake any duty to update this information,
including any forward-looking statements, unless required by law.

For Research Use Only. Not for use in diagnostic procedures.

(C) 2005 Applera Corporation and MDS Inc. All Rights Reserved.

Applera is a trademark and Applied Biosystems is a registered trademark
of Applera Corporation or its subsidiaries in the U.S. and/or certain
other countries.

Analyst, Q TRAP, and QSTAR are registered trademarks of Applied
Biosystems/MDS SCIEX, a joint venture between Applera Corporation and
MDS Inc.


Contact Information